

NEL Primary and Secondary Care Adult Asthma Prescribing Guidelines

Docu	ment control						
ersi	on	2 (updated 06/2023)					
	ous version	1 (approved 12/2022)					
Date a	approved	04/07/2023 (North East London Formulary and Pathways Group)					
Date	atified	25/07/2023 (North East London Integrated Medicines Optimisation and Prescribing Group)					
Revie	w date	12/2025					
Page	Contents						
1	Content page						
	Abbreviations Introduction						
2	Table 1 Asthm	a Guideline with Dry Powder Inhaler (DPI) options					
3	3 Table 2 Asthma Guideline with Metered Dose Inhaler (MDI)						
	options						
4 Asthma check li		list cycle que considerations					
	Asthma Symp	tom Control					
	Mometasone Enerzair® Bree	potency equivalence for Atectura® Breezhaler® and ezhaler®					
5	Adherence gu						
	Stepping up a Steroid use co	nd down asthma treatment nsiderations					
	References						
6	Appendix 1 Ex	ample MART action plan					
7	Appondix 2 Fr	ample inhalors for asthma management with images					
7	Appendix 2 Ex	ample inhalers for asthma management with images					

Introduction

This updated guideline focuses on ensuring that the most clinically effective, green, and cost-effective asthma treatments are those that a patient will and can take correctly. It highlights the importance of competent inhaler technique assessment and adherence considerations before deciding on the drug molecule. The guide also promotes prescribing by brand and device as well as combination inhalers over separate inhalers prescribing. It supports choosing inhalers devices requiring similar inhalation technique. These will in turn drive our agenda of improved asthma care and greener inhaler outcomes. In addition, we also advise on MART therapy as an alternative to traditional separate reliever and fixed dose preventer inhalers highlighting the future direction of where MART sits within asthma treatment ladder. This will support the drive away from SABA reliance and positively impact clinical care and the NHS low carbon agenda.



First assess Inhaler Technique to decide if patients could use Dry Powder Inhaler devices.

See Table 1 for patients with ability and shared decision to use Dry Powder Inhaler (DPI) devices as first line supporting the green agenda.

			Asthma Guidelines DI		
	ekly and consider moving pa e if patients have ≥ 2 exace			nain uncontrolled despite optimising patient's p k factors and treatment.	personalised asthma care
Step 1 and	Step 2	Step 3		der referral to secondary care for asthma p	henotyping and
New Diagnosis	· · ·	•	consideration for bi	,	
PRN low dose	Maintenance and Reliever	Therapy (MART) REGIME	NS		
combination ICS-					
ormoterol reliever use					
Patients with infrequent symptoms and with no	Fostair [®] NEXThaler [®] 100/6	(max 8 puffs daily)			
exacerbation risk factors:	Symbicort [®] Turbohaler [®] 200/6 (max 8 puffs daily)		Specialist care may r	prescribe a high-dose ICS containing fixed-dos	o proventor with MART
	Dose: 1 to 2 puffs BD and a			high-risk patients with concerns of adherence a	
Turbohaler [®] 200/6	Consider MART for all patier	ts and narticularly those			
Dose: 1 puff as needed	likely to be non-adherent to	regular ICS preventer			
(max 8 puffs daily) therapy. Stop PRN SABA		ile on MART*.			
· · · · · · · · · · · · · · · · · · ·	FER AND RELIEVER REGIN	IENS			
	ed alongside fixed dose ICS		Salbutamol Easyhaler	100mcg 1- 2 puffs PRN	
Low Dose	Low Dose	Medium Dose		High Dose	High Dose Triple
ICS	ICS/LABA	ICS/LABA		ICS/LABA	ICS/LABA/LAMA
D				Atectura [®] Breezhaler [®] 125/260mcg	
Beclometasone Easyhaler®	Atectura [®] Breezhaler [®] 125/62.5mcg	Atectura [®] Breezhaler [®] 125/127.5mcg	Eosinophils ≥0.3 on treatment	1 puff OD	Enerzair [®] Breezhaler [®] 114/46/136 mcg
200mcg 1 puff BD	1 puff OD	1 puff OD	ueauneni	Fostair [®] NEXThaler [®] 200/6 mcg (note	1 puff OD
	, pan eb			contains 120 doses) 2 puffs BD	
Pulmicort [®] Turbohaler [®]	Fostair [®] NEXThaler [®]	Fostair [®] NEXThaler [®]		, ,	
200mcg	100/6 mcg	100/6 mcg		Relvar [®] Ellipta [®] 184/22 mcg	
1 puff BD	1 puff BD	2 puffs BD		1 puff OD	_
	Cymrae i a an t® Tyyre a balan®	Relvar [®] Ellipta [®]		Medium Dose Triple (Note licensing for	
All patients who	Symbicort [®] Turbohaler [®] 200/6 mcg	92/22mcg 1 puff OD	Eosinophils <0.3	COPD i.e. airways obstruction)	
report any SABA	1 puff BD	o 1.1 (@	and / or with		
usage must be	, pan 22	Symbicort [®] Turbohaler [®] 200/6 mcg	obstructive	Trelegy [®] Ellipta [®] 92/55/22 mcg	
on inhaled		2 puffs BD	spirometry	1 puff OD	
steroids.					
	(+/- Montelukast 10mg	(+/- Montelukast 10mg		Trimbow [®] NEXThaler [®] 88/5/9 mcg	
	ON) Consider 6-week trial and stop if no benefit,	ON) Consider 6-week		2 puffs BD	
	caution neuropsychiatric	trial and stop if no benefit, caution			
	SEs	neuropsychiatric SEs			
D. Jukalana ana liata din	alahahating Landon and matin			one-off rescue pack Salamol® MDI 100 via	

N.B. Inhalers are listed in alphabetical order and not in order of preferences. *Consider prescribing a one-off rescue pack Salamol® MDI 100 via spacer and teach patient tidal breath technique for use in an asthma exacerbation emergency.




For patients unsuitable for DPI devices, see Table 2 for Metered Dose Inhaler (MDI) options to be used via spacers

		Table 2. Adult As	sthma Guidelines MI	DI options		
				emain uncontrolled despite opt able risk factors and treatme	imising patient's personalised asthma n t.	
Step 1 New Diagnosis	Step 2	Step 3	Steps 4 and 5 consider referral to secondary care for asthma phenotyping and consideration for biologics.			
PRN low dose combination ICS- formoterol reliver use	Maintenance and Reliever	Therapy (MART) REGIME	NS			
Dose: 1 puff as needed Consider MART for all patients and particularly those		Specialist care may prescribe a high-dose ICS containing fixed-dose preventer with MART reliever for selected high-risk patients with concerns of adherence and life-threatening exacerbations off license.				
(max 8 puffs daily)	therapy. Stop PRN SABA w	hile on MART*.				
PRN SABA to be used a	TER AND RELIEVER REG alongside fixed dose ICS col eath technique via spacer	ntaining options below: Sala				
Low dose ICS	Low dose ICS/LABA	Medium dose ICS/LABA	Eosinophils ≥0.3	High Dose ICS/LABA	High Dose Triple ICS/LABA/LAMA Trimbow [®] MDI 172/5/9 mcg	
Soprobec [®] MDI 200 mcg	Luforbec [®] MDI 100/6 mcg	Luforbec® MDI 100/6 mcg	on treatment	Luforbec [®] MDI 200/6 mcg 2 puffs BD via spacer	2 puffs BD via spacer	
1 puff BD Via spacer	1 puff BD via spacer Combisal [®] MDI	2 puffs BD via spacer Combisal [®] MDI		Combisal [®] MDI 250/25 mcg 2 puffs BD via spacer		
All patients who report any SABA usage must be	50/25mcg 2 puffs BD via spacer	125/25mcg 2 puffs BD via spacer	Eosinophils <0.3 and / or with	Medium Dose Triple ICS/LABA/LAMA		
on inhaled steroids.	(+/- Montelukast 10mg ON) Consider 6-week trial and stop if no	(+/- Montelukast 10mg ON) Consider 6-week trial and stop if no	obstructive spirometry	Trimbow [®] MDI 87/5/9 mcg 2 puffs BD via spacer		
	benefit, caution neuropsychiatric SEs	benefit, caution neuropsychiatric SEs				

N.B. Inhalers are listed in alphabetical order and not in order of preferences. *Consider prescribing a one-off rescue pack Salamol® MDI 100 via spacer and teach patient tidal breath technique for use in an asthma exacerbation emergency. ** Current unlicensed use but equivalent to Symbicort Turbohaler on DPI section (NEL respiratory network consensus to include the use of a combination ICS-formoterol MDI product in Step 1 for PRN use).



Asthma checklist cycle for personalised asthma care for all patients (Adapted from GINA 2021)





Adherence to inhaled steroid containing therapy and Support

FeNO suppression readings where available

Inhaler dose counter checks and electronic sensors data where available

Medication Possession Ratio (MPR)- calculation via prescription refill data

<u>No. of doses prescribed (in a fixed time frame)</u> X 100% No. of doses expected (in the same fixed time frame)

E.g. patient on Symbicort® 400/12 turbohaler at 2 puffs bd (60doses/inh) and collects 1 inhaler monthly over 12 month period on GP records MPR % = 60 doses x 12 months x 100% = 50%

 $\frac{MPR \%}{4doses x 30days x 12months} x 100\% = 50\%$

Good Adherence	Suboptimal	Poor
≥75%	50- 74%	<50%

3min Test of Adherence to Inhalers (TAI) self Questionnaire to help identify non-adherence

https://taitest.com/

https://www.taitest.com/docs/Guia Usuario TAI EN.pdf

Examples of unintentional non-adherence	Suggested Support
Critical errors with inhaler technique	Correction and optimising technique via a competent HCP
Financial barriers	Suggest pre-payment certificates; increasing quantities of inhalers per prescription
Forgets	Phone reminders, consider inhalers with OD dosing pending suitable inhaler technique
Poor understanding of disease and treatment	Education support

Steroids

Gradual withdrawal of oral steroids should be considered in the following patients:

- Received more than 40mg prednisolone (or equivalent) daily for more than 1 week.
- Been given repeated doses in the evening
- Received more than 3 weeks' treatment
- Recently received repeated courses
- Taken a short course within 1 year of stopping long term therapy

A Blue steroid treatment card and a Red Steroid Emergency Card with Sick day rule counselling should be issued to the following patients

- Receiving high dose ICS (>1000BDP or equivalent)
- On long term oral steroids e. prednisolone 5mg daily or equivalent for 4 weeks or longer and for 12 months after stopping oral steroids
- Taking 40mg prednisolone daily or equivalent for longer than 1 week or repeated short courses of oral corticosteroids.
- Patients taking concurrent steroids via multiple routes (e.g. inhaled and/ or oral steroids with intramuscular or intra-articular glucocorticoid injections)

https://www.england.nhs.uk/2020/08/steroid-emergency-card-to-support-early-recognition-and-treatment-of-adrenal-crisis-in-adults/

https://www.endocrinology.org/adrenal-crisis

Stepping up treatment

Check patients asthma control based on symptoms, limitation of activities and use of rescue medication.

Numerical asthma control tools for assessing symptom control are: ACQ (asthma control questionnaire) and Asthma Control Test (ACT).

Consider increasing preventer therapy if using short acting beta agonist 3 times a week or more.

All patients should have their adherence checked prior to increasing or commencing new asthma treatments.

Any patients not responding to ICS/LABA treatment should have their diagnoses confirmed before increasing treatment.

Are symptoms due to comorbid conditions e.g. chronic rhinitis, gastroesophageal reflux

Stepping down treatment

Consider stepping down when good asthma control has been achieved and maintained for 12 months, to find the lowest treatment that controls the patients symptoms and minimises exposure to side effects.

Choose an appropriate time for step-down (no respiratory infection, patient not travelling, not pregnant).

Step down to reduce the ICS dose by 25-50% at yearly intervals .

References

- BTS/SIGN Asthma Guidelines 2019. The BTS/SIGN Guideline for the management of asthma published on July 2019.
- NICE Asthma: diagnoses, monitoring and chronic asthma management guidelines published February 2020.
- UK Inhaler group. Inhaler standards and competency document. Scullion J, Respiratory Nurse Consultant, University hospital of Leicester NHS Trust. Contributors Murphy, Anna. Consultant Pharmacist, University Hospitals of Leicester. Published December 2019.
- Global Initiative for Asthma. Global Strategy for Asthma management and prevention. 2022 update.
- Electronic British National Formulary. BMJ Group and Pharmaceutical Press. Accessed Aug 2022
- Electronic Medicines Compendium. Medicines.org.uk/emc/ Accessed September 2022
- QOL Tech. Measurement of Health-Related Quality of life & Asthma control. 1999; Available at: <u>https://www.goltech.co.uk/miniaglg.html.</u> Accessed October 2022.
- Asthma.com. Asthma Control Test Available at: <u>http://www.asthma.com/additional-resources/asthma-control-test.html</u>. Accessed October 2022.



ASTHMA Maintenance and Reliever Therapy (MART) ACTION PLAN

MART is a combined ICS and LABA treatment in a single inhaler, containing both ICS and a fast-acting LABA. It is used for both daily maintenance therapy and the relief of symptoms as required. Licensed MART Inhalers include: Fostair[®] NEXThaler[®] 100/6; Symbicort[®] Turbohaler[®] 200/6; Duoresp[®] Spiromax 160/4.5; Fobumix[®] Easyhaler 160/4.5; Luforbec[®] MDI 100/6; Fostair[®] MDI 100/6

CONTROLLED ASTHMA	INCREASING ASTHMA SYMPTOMS	ASTHMA EMERGENCY
My asthma is WELL CONTROLLED when:	If over a period of two to three days my asthma is	SIGNS OF AN EMERGENCY
I have no difficulty sleeping because of my asthma	GETTING WORSE when:	My MART inhaler is not relieving my symptoms.
symptoms.	My asthma is causing me to wake during night-time or	I am having extreme difficulty in breathing.
I have no symptoms of wheeze, cough or chest	early morning.	I am too breathless to speak in full sentences.
tightness day or night.	I am having difficulty at work or play because of my	
I can "work & play" without difficulty.	breathing.	My peak flow is (Less than 50% of my
I do not need additional puffs of my asthma	I have cough, wheeze, or chest tightness which causes	usual best).
medication.	me to need my reliever three times a week or more.	
		Sit upright and keep calm. Loosen tight clothing.
Usual best peak flow:L/min	I should continue my MART Inhaler twice daily and	
	when required, and	Take one puff immediately. (If I am using an MDI
My MART Inhaler is	I should check my peak flow	device take one puff through my spacer). Then try
·		taking slow steady breaths.
	If my peak flow is less than (75 % of my best)	
My regular maintenance dose is:	AND/ OR I'm using 6 or more puffs a day of my	If there is no improvement take another puff of my
puff/s morning and evening. (Use spacer if	inhaler for a period longer than a few days, please	inhaler every 2 minutes up to a maximum of 8 puffs in
your inhaler is an MDI)	make an appointment with your GP practice for a	total. If I do not feel better after taking my inhaler as
	review.	instructed above:
My reliever dose is: One additional puff when needed		- SEEK MEDICAL ADVICE IMMEDIATELY BY
for relief of my asthma symptoms up to a maximum of	IF I SUDDENLY FEEL WORSE or IF THERE IS NO	CALLING 999 OR GO DIRECTLY TO HOSPITAL
8 puffs in a day.	IMPROVEMENT AND:	
	I have been prescribed a rescue pack of Prednisolone,	- If my symptoms improve, still make an urgent
	I should contact my GP practice for advice on whether	same day appointment with the GP practice
	to start these for at least 5 days or until better. If	for a review.
	unable to contact GP, then I should start the pack.	
	If I do not have rescue steroids, I should contact my	
	GP practice for an urgent review.	



Appendix 2 Example Inhalers used in asthma management with images. See NEL formulary for full list

ICS		ICS/LABA		ICS/LABA/LAMA	
DPI 🕥	MDI	DPI ⊘	MDI	DPI 🙆	MDI
Beclometasone Easyhaler® 200mcg Pulmicort Turbohaler® (Budesonide) 100, 200, 400mcg Budesonide Easyhaler® 100, 200, 400mcg	Clenil Modulite®MDI (Beclometasone) 100, 200mcg Sobrobec® MDI (Beclometasone) 100, 200, 250mcg	Budesonide/ Formoterol Duoresp Spiromax® 160/4.5mcg (MART); 320/9 Fobumix Easyhaler® 80/4.5mcg (MART); 160/4.5mcg (MART); 320/9mcg Symbicort Turbohaler® 100/6 (MART); 200/6 (MART); 400/12 Fostair NEXThaler® 100/6 (MART); 200/6 (Beclometasone/ Formoterol) Fusacomb Easyhaler® 250/50; 500/50mcg (Fluticasone propionate/ Salmeterol) Relvar Ellipta® 92/22; 184/22mcg (Fluticasone Furoate/ Vilanterol) Elipta® 92/22; 184/22mcg (Fluticasone Furoate/ Vilanterol) Atectura Breezhaler® 125/62.5; 125/127.5; 125/260mcg (Indacterol/ Mometasone)	Beclometasone/ Formoterol Fostair® MDI 100/6 (MART); 200/6 Luforbec® MDI 100/6 (MART); 200/6 Eluficasone propionate/ Salmeterol Combisal® MDI 50/25; 125/25; 250/25 Sereflo® MDI 125/25; 250/25 Seretide® MDI 50/25	Enerzair Breezhaler® 114/46/136mcg (Indacaterol/ Glycopyrronium/ Mometasone)	Trimbow ®MDI 87/5/9; 172/5/9mcg (Beclometasone/ Formoterol/ Glycopyrronium)

	Spacer to prescribe with MDIs:			
DPI 🕥		MDI	Aerochamber Plus Flow-Vu Mouthpiece	
Salbutamol Easyhaler® 100mcg		Salamol® MDI 100mcg (Salbutamol)		
Bricanyl Turbohaler® 100mcg (Terbutaline) 🛛 💼 🔤			Low carbon footprint device choice	
			7 P a g	g e